On August 2, 2022, Coherus BioSciences announced that the U.S. Food and Drug Administration (FDA) has approved CIMERLI™ (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis® (ranibizumab injection) for all five indications, meeting the FDA’s rigorous standards to the reference
The Hook ’em Horns of the University of Texas earned a big win in a recent trademark opposition proceeding. This is an interesting sports trademark case.
The case, the Board of Regents of the University of Texas v. Kendall A.
A recent appeal of a trademark application refusal shows the importance of filing proper specimens of use.
The matter, In Re Sciton, Inc., was an appeal filed by the owner of two applications to register the mark SCITON (in
A trademark registration for the mark PROHEAR for audio headphones and related goods has been cancelled based on a likelihood of confusion with the mark PROTEAR for similar goods. The trademark cancellation proceeding was filed and decided before the U.S.
Recently, the Patent Trial and Appeal Board (PTAB) announced a new interim procedure for decision circulation and internal review. This interim procedure is aimed at promoting feedback, eliminating inconsistencies, and increasing transparency during the decision pre-issuance process. The push for
On April 13, 2022, the European Commission submitted a proposed regulation on the protection of Geographical Indications for Craft and Industrial Products (CIPs), along with amendments to existing EU regulations on trademark registration and accession to the Geneva Act of
Patent thickets, particularly those involving pharmaceutical patents, appear to have caught the ire of many U.S. senators. Within the past few weeks, two separate letters have urged action to find ways to prevent issuance of overlapping patents covering a single
Introduction
For many start-up companies, the prospect of filing a patent application can be daunting. Even when a company has a potentially patentable invention, the company may be unsure about what materials it should compile before seeking out patent counsel.
In light of Elon Musk’s recent offer to buy Twitter, Inc. (“Twitter”) there has been a resurgence in the desire to develop decentralized social media platforms. In efforts to avoid being at the whim of a single company or individual,
Patents related to Regeneron’s EYLEA (aflibercept) were recently added to the Purple Book. Under the Biological Product Patent Transparency Act, signed into law December 27, 2020 and codified at 42 U.S.C. § 262(k)(9), patents must be submitted to the